KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) EBITDA: 2009-2024

Historic EBITDA for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to -$69.6 million.

  • Arbutus Biopharma's EBITDA rose 60.59% to -$7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.3 million, marking a year-over-year increase of 44.25%. This contributed to the annual value of -$69.6 million for FY2024, which is 1.62% up from last year.
  • As of FY2024, Arbutus Biopharma's EBITDA stood at -$69.6 million, which was up 1.62% from -$70.8 million recorded in FY2023.
  • In the past 5 years, Arbutus Biopharma's EBITDA registered a high of -$63.7 million during FY2020, and its lowest value of -$76.4 million during FY2021.
  • In the last 3 years, Arbutus Biopharma's EBITDA had a median value of -$70.8 million in 2023 and averaged -$70.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 58.59% in 2020, then dropped by 19.98% in 2021.
  • Arbutus Biopharma's EBITDA (Yearly) stood at -$63.7 million in 2020, then decreased by 19.98% to -$76.4 million in 2021, then climbed by 6.28% to -$71.6 million in 2022, then grew by 1.15% to -$70.8 million in 2023, then rose by 1.62% to -$69.6 million in 2024.